This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Hologic (HOLX) 주식 개요
는 조기 발견 및 치료를 통해 전 세계 여성 건강을 위한 진단 제품, 의료 영상 시스템 및 수술 제품을 개발, 제조 및 공급하는 회사입니다. 자세히 보기
HOLX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hologic, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$76.01 |
| 52주 최고가 | US$76.07 |
| 52주 최저가 | US$51.90 |
| 베타 | 0.70 |
| 1개월 변동 | 0.36% |
| 3개월 변동 | 1.47% |
| 1년 변동 | 24.06% |
| 3년 변동 | -8.50% |
| 5년 변동 | 2.14% |
| IPO 이후 변동 | 3,079.50% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Apr 10
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading
Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.내러티브 업데이트 • Mar 26
HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes
Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.내러티브 업데이트 • Mar 12
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes
Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.내러티브 업데이트 • Feb 26
HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path
Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.Recent updates
내러티브 업데이트 • Apr 10
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading
Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.내러티브 업데이트 • Mar 26
HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes
Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.내러티브 업데이트 • Mar 12
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes
Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.내러티브 업데이트 • Feb 26
HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path
Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.내러티브 업데이트 • Feb 11
HOLX: Buyout Terms And Neutral Ratings Will Shape Event-Driven Returns Through 2026
Analysts have trimmed their fair value estimate for Hologic to US$76.60 from about US$76.92, citing recent downgrades to Hold and Neutral, as the pending US$79 per share buyout by Blackstone and TPG narrows the expected upside. Analyst Commentary Recent research updates around Hologic largely reflect the pending all cash acquisition at US$79 per share, with several firms moving to more neutral stances as the share price tracks closer to the agreed takeout level.내러티브 업데이트 • Jan 26
HOLX: Buyout Terms And Neutral Ratings Will Frame Returns Through 2026
Narrative Update The analyst fair value estimate for Hologic has edged up by about $0.50 per share as analysts align their targets more closely with the pending private equity acquisition price of up to $79. They are also updating assumptions around the discount rate, modest revenue growth, and future P/E.내러티브 업데이트 • Jan 12
HOLX: Buyout Deal Terms And Rating Downgrades Will Guide Trading Through 2026
Our updated analyst price target for Hologic edges down slightly to about $76.42 per share. This reflects that analysts now anchor their views more tightly to the proposed Blackstone and TPG takeout value of up to $79 per share and the recent wave of rating downgrades to Neutral or Hold around that deal.내러티브 업데이트 • Dec 18
HOLX: Buyout Terms And Neutral Ratings Will Shape Trading Through 2026
We trim our Hologic price target slightly to approximately $76.50, as analysts coalesce around the proposed Blackstone and TPG takeout valuation of up to $79.00 per share and see limited upside beyond the agreed acquisition terms. Analyst Commentary Street research following the announced takeout has converged around the proposed valuation, with most firms adjusting ratings and targets to reflect a view that the deal price largely caps near term upside.내러티브 업데이트 • Dec 04
HOLX: Buyout Deal And Neutral Ratings Will Define Shares Through 2026
The analyst price target for Hologic has inched higher by approximately $0.33 to $76.50, as analysts factor in slightly stronger long term growth and margin assumptions while anchoring valuation to the proposed Blackstone and TPG takeout price near $79 per share. Analyst Commentary Analyst reaction to the proposed Blackstone and TPG acquisition has been mixed, with most firms converging around price targets in the mid to high $70s and resetting ratings to more neutral stances as upside becomes more constrained by the agreed takeout price.내러티브 업데이트 • Nov 20
HOLX: Acquisition Agreement With Blackstone and TPG Will Shape Stock Outlook Through 2026
Hologic’s analyst price target has increased modestly from $75.08 to $76.17 per share. Analysts view the proposed $79 per share acquisition by Blackstone and TPG as providing a fair valuation and setting a near-term ceiling for the stock.내러티브 업데이트 • Nov 05
HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance
Analysts have modestly increased their price target for Hologic from approximately $73.54 to $75.08. They cite the recently announced acquisition by Blackstone and TPG as supportive of current valuation levels, given the company's operating challenges and outlook.내러티브 업데이트 • Oct 22
Analysts Raise Hologic Targets Amid Strong Results and Positive Acquisition Momentum
Hologic's analyst price target has increased by $1.11, as analysts cite improving financial performance and the impact of the recent acquisition agreement as key factors that support the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts increased their price targets, pointing to Hologic's improved financial results and raised full-year guidance amid strong recent revenue and EPS performance.내러티브 업데이트 • Sep 28
Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets
Despite strong quarterly outperformance, higher 2025 guidance, and increased buyout speculation, Hologic's consensus analyst price target was modestly reduced from $73.87 to $72.43 as fiscal 2025 estimates were recalibrated to reflect current demand trends and tariff expectations. Analyst Commentary Strong revenue and EPS outperformance in the recent quarter, with management raising full-year 2025 guidance.분석 기사 • Sep 13
Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...내러티브 업데이트 • Sep 05
Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets
Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks. Analyst Commentary Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.분석 기사 • Aug 04
Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report
Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...분석 기사 • Jul 19
Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$103 Hologic is estimated to...분석 기사 • Jul 01
The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)
With a price-to-earnings (or "P/E") ratio of 26.1x Hologic, Inc. ( NASDAQ:HOLX ) may be sending bearish signals at the...분석 기사 • Jun 13
Is Hologic (NASDAQ:HOLX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • May 06
Hologic: Soft Performance, But Cheap Enough
Summary Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. While cautious due to recent underperformance and expensive acquisitions, I remain upbeat on HOLX stock and plan to add to my long position. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
Hologic: Reasonably, But Not Compellingly Valued
Summary Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions. Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 28
Hologic: Continued Room Amidst Bolt-On M&A Efforts
Summary Hologic, Inc.'s focus on women's health and strategic M&A, despite pandemic headwinds, positions it for continued growth with a projected $4 billion revenue in 2024. Trading at 20 times earnings, Hologic's quality and growth potential justify its valuation, with shares having risen 10% since May. The company maintains solid organic growth, reducing net debt and executing strategic acquisitions like Endomagnetics and Gynesonics, enhancing its market position. With pandemic-related diagnostics sales declining, Hologic's consistent earnings and strategic moves make it a compelling investment, despite shares not being cheap. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them
Summary Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, Breast Health, and Surgical segments, but Skeletal Health faced setbacks due to supplier issues. Management has continued to optimize the pandemic-driven surge in Panther placements, with the BV CV/TV panel growing to the second-largest panel in the company's portfolio. Hologic has been a share gainer in molecular diagnostics and is active in M&A, but long-term 5% to 7% revenue growth targets may be too challenging. Long-term revenue growth around 5%, near-term EBITDA margins in the low-30%s, and long-term FCF growth of around 6% support today's valuation and single-digit returns, but Hologic doesn't stand out as undervalued. Read the full article on Seeking Alpha주주 수익률
| HOLX | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | 0.6% | 3.0% | -0.8% |
| 1Y | 24.1% | -18.3% | 27.1% |
수익률 대 산업: HOLX은 지난 1년 동안 -18.3%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: HOLX은 지난 1년 동안 27.1%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| HOLX volatility | |
|---|---|
| HOLX Average Weekly Movement | 0.4% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: HOLX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: HOLX의 주간 변동성(0%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1985 | 7,070 | Steve MacMillan | www.hologic.com |
는 조기 발견 및 치료를 통해 전 세계 여성 건강을 위한 진단 제품, 의료 영상 시스템 및 수술용 제품을 개발, 제조 및 공급하는 회사입니다. 이 회사는 네 가지 부문으로 운영됩니다: 진단, 유방 건강, 부인과 수술, 골격 건강입니다. 이 회사는 감염성 미생물을 검출하는 앱티마 분자 진단 분석과 B형 간염 바이러스, C형 간염 바이러스, 인간 면역 결핍 바이러스, 인간 거대 세포 바이러스에 대한 앱티마 바이러스 부하 분석을 제공합니다; 질염 진단을 위한 앱티마 세균성 질염 및 칸디다 질염 분석, 사스 코로나바이러스-2 검출을 위한 앱티마 사스 코로나바이러스-2 및 팬더 퓨전 사스 코로나바이러스-2 분석, 세포학 애플리케이션을 위한 씬프렙 시스템, 의사의 조산 위험 평가를 지원하는 신속 태아 피브로넥틴 테스트 등이 있습니다.
Hologic, Inc. 기초 지표 요약
| HOLX 기초 통계 | |
|---|---|
| 시가총액 | US$16.89b |
| 순이익 (TTM) | US$543.80m |
| 매출 (TTM) | US$4.13b |
31.2x
주가수익비율(P/E)4.1x
주가매출비율(P/S)HOLX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| HOLX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$4.13b |
| 매출원가 | US$1.64b |
| 총이익 | US$2.49b |
| 기타 비용 | US$1.95b |
| 순이익 | US$543.80m |
최근 보고된 실적
Dec 27, 2025
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 2.44 |
| 총이익률 | 60.38% |
| 순이익률 | 13.18% |
| 부채/자본 비율 | 47.8% |
HOLX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/04/06 16:33 |
| 종가 | 2026/04/06 00:00 |
| 수익 | 2025/12/27 |
| 연간 수익 | 2025/09/27 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Hologic, Inc.는 25명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |